In a retrospective chart review, IV ketamine led to in a 50% reduction in pain at discharge, with “nearly two-thirds” of patients having no recurrence within 30 days, lead investigator Scott Rosenthal, [instructor/fellow of pediatrics, Section of Neurology] from the University of Colorado Anschutz Medical Campus, Aurora, noted. Rosenthal reported the findings (Abstract S20.010) on April 15 at the American Academy of Neurology 2024 annual meeting.